The first report of CCR5 delta 32 mutant in Thai injecting drug users

Asian Pacific Journal of Allergy and Immunology

Volumn 18, Issue 2, 2000, Pages 93-98

  Ruchusatsawat, Nuanjun ^a   Vongsheree, Suthon ^a   Thaisri, Hansa ^a   Phutiprawan, Tippawan ^b  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b Thanyarak hospital   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; DNA; MUTANT PROTEIN;

ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; GENE DELETION; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; THAILAND; VIRUS TRANSMISSION;

ADULT; ALLELES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; GENOTYPE; HETEROZYGOTE; HIV INFECTIONS; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; MUTATION; PREVALENCE; RECEPTORS, CCR5; SUBSTANCE ABUSE, INTRAVENOUS; THAILAND;

EID: 0033911101     PISSN: 0125877X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Cocchi F, DeVico AL, Garziine-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1α and MIP-1β as the major HIV-suppressive factors produced by CD8+ T-cells. Science 1995; 270: 1181-5.
2. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381: 661-6.
3. Doranz BJ, Rucker J, Yi Y, et al. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996; 85: 1149-58.
4. Choe H, Farzan M, Sun Y, et al. The beta-chemokine receptor CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996; 85: 1135-48.
5. Liao F, Alkhatib G, Peden KW, Sharma G, Berger EA, Farber JM. STRL33, a novel chemokine receptor-like protein, function as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1. J Exp Med 1997; 185: 2015-23.
6. Moore JP, Trkola A, Dragic T. Co-receptors for HIV-1 entry. Curr Opin Immunol 1997; 9: 551-62.
7. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use correlates with disease progression in HIV-1 infected individuals. J Exp Med 1997; 185: 621-8.
8. Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381; 667-73.
9. Alkhatib G, Combadiere C, Broder CC, et al. CC-CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272: 1955-8.
10. Bleul CC, Farzan M, Choe H, et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996; 382: 829-33.
11. Oberlin E, Amara A, Bachelerie F, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line adapted HIV-1. Nature 1996; 382: 833-5.
12. Berson JF, Long D, Doranz BJ, Rucker J, Jirik FR, Doms RW. A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains. J Virol 1996; 70: 6288-95.
13. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G-protein-coupled receptor. Science 1996; 272: 872-7.
14. Lapham CK, Ouyang J, Chandrasekhar B, Nguyen NY, Dimitrov DS, Golding H Evidence for cell-surface assocoation between fusin and the CD4-gp120 complex in human cell lines. Science 1996; 274: 602-5.
15. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382: 722-5.
16. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996; 273: 1856-61.
17. Zimmerman PA, Buckler-White A, Alkhatib G, et al. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: Studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Molec Med 1997; 3:23-36.
18. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86: 367-77.
19. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nature Med 1996; 2: 1240-3.
20. Micheal NL, Chang G, Luoie LG, et al. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Natare Med 1997; 3: 338-40.
21. Biti R, Ffrench R, Young J, Bennetts B, Stewart G, Liang T. HIV-1 infection in an individual homozygous for the CCR5 deletion allele. Nature Med 1997; 3: 252-3.
22. Eugen-Olsen J, Iversen AKN, Garred P, et al. Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS free survival and slower CD4 T cell decline in a cohort of HIV-sero-positive individuals. AIDS 1997; 11: 305-10.
23. Meyer L, Magierowska M, Hubert JB, et al. Early protective effect of CCR-5 A32 heterozygosity on HIV-1 disease progression: relationship with viral load. The SEROCO Study Group. AIDS 1997; 11:F73-8.
24. Lucotte G, Mercier G. Distribution of CCR5 gene 32-bp deletion in Europe. J Acquir Immune Defic Syndr Human Retrovirol 1998; 19: 174-7.
25. Nasioulas G, Dean M, Koumbarelis E, et al. Allele frequency of the CCR5 mutant chemokine receptor in Greek Caucasians. J Acquir Immune Defic Syndr Human Retrovirol 1998; 17: 181-2.
26. Alvarez V, Lopez-larrea C, Coto E. Mutational analysis of the CCR5 and CXCR4 genes (HIV-1 co-receptor) in resistance to HIV-1 infection and AIDS development among intravenous drug users. Hum Genet 1998; 102: 483-6.
27. Martinson JJ, Chapman NH, Rees DC, Liu YT, Clegg JB. Global distribution of the CCR5 gene 32-basepair deletion. Nature Genet 1997, 16: 100-3.
28. Husain S, Goila R, Shahi S, Banerjea A. First report of a healthy Indian heterozygous for delta 32 mutant of HIV-1 co-receptor-CCR5 gene. Gene 1998; 207: 141-7.
29. Li C, Yan YP, Shieh B, Lee CM, Lin RY, Chen YM. Frequency of the CCR5 delta 32 mutant allele in HIV-1 positive patients, female sex workers, and a normal population in Taiwan. J Formos Med Assoc. 1997; 96: 979-84.
30. Jiang JD, Wang Y, Wang ZZ, et al. Low frequency of the ccr5delta32 HIV-resistance allele in mainland China: Identification of the first case of ccr5delta32 mutation in the Chinese population. Scand J Infect Dis 1999; 31: 245-8.
31. Pau CP, Lee-Thomas S, Auwanit W, et al. High specific V-3 peptide enzyme immunoassay for serotyping HIV-1 specimens from Thailand. AIDS 1993; 7: 337-40.
32. rd ed. Boston: PWS-KENT Publishing, 1989.
33. Beyrer C, Artenstein AW, Rugpao S, et al. Epidemiologic and biologic characterization of a cohort of human Immunodeficiency virus type 1 highly exposed, persistently seronegative female sex workers in northern Thailand. J Infect Dis 1999; 179: 59-67.
34. Kokkotou E, Philippon V, Gueye-Ndiaye A, et al. Role of the CCR5 delta 32 allele in resistance to HIV-1 infection in West Africa. J Hum Virol 1998. 1: 469-74.
35. Hoffman TL, MacGregor RR, Burger H, Mick R, Doms RW, Collman RG. CCR5 genotypes in sexually active couples discordant for human immunodeficiency virus type 1 infection status. J Infect Dis 1997; 176: 1093-6.
36. Rousseau CM, Just JJ, Abrams EJ, Casabona J, Stein Z, King MC. CCR5 de132 in perinatal HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16: 239-42.
37. Edelstein RE, Arcuino LA, Hughes JP, et al. Risk of mother-to-infant transmission of HIV-1 is not reduced in CCR5/delta32CCR5 heterozygotes. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16: 243-6.
38. Quillent C, Oberlin E, Braun J, et al. HIV-1 resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet 1998; 351: 14-8.
39. Ansari-Lari MA, Lui X-M, Metzker ML, Rut AR, Gibbs RA. The extent of genetic variation in the CCR5 gene. Nat Genet 1997; 16: 221-2.
40. Carrington M, Kissner T, Gerrard B, Ivanov S, O'Brien SJ, Dean M. Novel allele of the chemokine receptor gene CCR5. Am J Hum Genet 1997; 61: 1261-7.
41. Schinkel J, Langendam MW, Coutinho RA, Krol A, Brouwer M, Schuitemaker H. No evidence for an effect of the CCR5 30/+ and CCR2b 641/+ mutations on human immunodeficiency virus (HIV-1 disease progression among HIV-1 infected injecting drug users. J Infect Dis 1999; 179: 825-31.
42. Quillent C, Oberlin E, Braun J, et al. HIV-1 resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet 1998; 351: 14-8.
43. Carrington M, Kissner T, Gerrard B, Ivanov S, O' Brien SJ, Dean M. Novel alleles of chemokine-receptor gene CCR5. Am J Hum Genet 1997; 61: 1261-7.
44. Ansari-Lari MA, Liu XM, Metzker ML, Rut AR, Gibbs RA. The extent of genetic variation in the CCR5 gene. Nat Genet 1997; 16: 221-2.
45. McDermott DH, Zimmerman PA, Guignard F, et al. CCR5 promoter polymorphism and HIV-1 disease progression. Lancet 1998; 352: 866-70.